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ABSTRACT 
 
Background 
In the UK, totally implantable venous access systems (TIVAS) are not routinely used.  
Compared with Hickman catheters, these devices are more expensive and complex to insert.  
However, it is unclear whether the higher costs may be offset by perceived greater health 
benefits.  This pilot trial aimed to generate relevant data to inform the design of a larger 
definitive randomised controlled trial. 
 
Methods 
This was a phase II prospective, randomised, open trial from two UK oncology centres.  The 
primary endpoint was overall complication rate.  Secondary endpoints included individual 
complication rates, time to first complication and quality of life.  Analysis was by intention to 
treat.  An economic evaluation was also carried out. 
 
Results 
100 patients were randomised in a 3:1 ratio to receive a Hickman or a TIVAS.  Overall, 54% 
of patients in the Hickman arm suffered one or more complications compared to 38% in the 
TIVAS arm (one-sided p=0.068).  In the Hickman arm, 28% of the devices were removed 
prematurely due to a complication compared to 4% in the TIVAS arm.  Quality of life based 
on the device-specific questionnaire was greater in the TIVAS arm for 13 of the 16 questions.  
The economic evaluation showed that Hickman arm was associated with greater mean cost 
per patient £1803 (95%CI 462, 3215), but similar quality adjusted life years (QALY) -0.01 
(95%CI -0.15, 0.15) than the TIVAS arm.  However, there is much uncertainty associated 
with the results. 
 
Conclusions 
Compared with Hickman catheters, TIVAS may be the cost-effective option.  A larger 
multicentre trial is needed to confirm these preliminary findings. 
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INTRODUCTION 
 
When intravenous chemotherapy is needed it can either be given though a peripheral 
cannula (typically in a forearm vein), or through a central venous access device where the 
catheter tip is placed in a large central vein (typically the superior vena cava).  Peripheral 
administration of chemotherapy frequently causes local vein irritation and thrombosis.  This 
results in rapid exhaustion of the forearm veins, interruption to treatment, patient discomfort 
and a genuine fear of cannulation (Cheung et al., 2009).  When the catheter tip lies centrally 
in a large vein, the damage is mitigated due to rapid blood flow and large vessel diameter.  
These advantages make central devices the obvious choice for longer drug regimes.  
 
There are three main types of central device: (i) tunnelled central catheter commonly referred 
to as a Hickman; (ii) peripherally inserted central catheter (PICC); and (iii) totally implanted 
venous access system (TIVAS) commonly referred to as a Port (Bishop et al., 2007).  A 
recent informal survey (personal communications) of nine large UK cancer units indicated 
Hickman (58%) to be the most common followed by PICC (33%), with TIVAS only used in 
9%. The TIVAS are more expensive, more complex and invasive to insert, and many 
healthcare staff are unfamiliar with their aftercare.  However, there is some evidence that 
TIVAS may have the lower complication rate and lead to greater patient satisfaction with less 
interruption to treatment regimens (Kulkarni et al., 2014).  The evidence is weak and the 
studies are heterogeneous, in terms of patient populations, methodological approach and 
definition of outcomes.  Therefore, the magnitude of this reduced risk is still unclear.  
 
There is a need to evaluate the value of these devices to the UK NHS by looking at clinical 
and cost-effectiveness.  It is unclear whether the higher purchasing costs of TIVAS may be 
offset by the perceived clinical benefits of lower complication rates and greater patient 
satisfaction.  This phase II pilot trial aimed to inform the design of a larger definitive 
randomised controlled trial (RCT) by generating information about potential recruitment rates, 
incidence and, distribution of outcome events, and the potential cost-effectiveness of the 
devices. 
 
ISRCTN79422566 
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METHODS 
 
Study design and participants 
This study was a phase II prospective, randomised, open trial conducted at two regional 
oncology centres in Scotland.  All oncology patients with solid tumours, aged 18 years and 
over, who required a central venous access device for the delivery of chemotherapy, were 
eligible to participate in the study.  Those who had evidence of any medical or psychiatric 
disorders that would be a contraindication to study participation and those with life 
expectancy of less than three months were excluded.  This trial was reviewed and approved 
by the Multicentre Research Ethics Committee (11/AL/0083). 
 
Randomisation and masking 
All eligible patients were centrally randomised using minimisation, with respect to body mass 
index (BMI; <20, 20 to <30, 30 to <40, ≥40), with a random element.  A 3:1 (Hickman:TIVAS) 
randomisation ratio was used because of the limited availability and the cost of TIVAS.  It 
was not feasible to mask participants and nurses to the allocated treatment. 
 
Procedures 
All devices were placed at one site under local anaesthesia with the patient option of 
conscious sedation.  A pre-procedure clotting screen was performed on all patients.  The INR 
had to be <1.5 and the platelet count > 50,000.  If either of these were abnormal then the 
appropriate corrective treatment administered (usually either a platelet transfusion and or 
fresh frozen plasma) as advised by the haematology department.  Hickman catheters were 
either single or double lumen; TIVAS were single lumen devices.  The majority of the devices 
were placed by senior interventional radiologists, with a small number of Hickman catheters 
placed by a nurse-led venous access team.  All devices were placed using jugular veins for 
access with ultrasound guidance.  The positioning of the Hickman catheters was confirmed 
by fluoroscopy or chest x-ray; fluoroscopy was routinely used to position the TIVAS.  A 
standardised approach to catheter care was adopted, which included weekly heparin 
(unfractionated 10units/ml) flush and dressing change for the Hickman catheters, and 
monthly heparin (unfractionated 10units/ml) flush for TIVAS.  Unlike the Hickman catheters, 
TIVAS were not in routine use at either of the two centres prior to the study.  Therefore, 
chemotherapy nursing staff received training prior to the start and during the study to 
minimise the potential impact of the ‘learning curve’.   
 
Outcomes 
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The primary endpoint was overall complication rate.  Complications included infection (blood 
stream infection, wound or exit site infection) and mechanical complications (line occlusion, 
migration, accidental withdrawal, flipping, central venous thrombosis, wound haematoma and 
skin breakdown or ulceration).  Secondary endpoints included incidences of individual 
complications, time to first complication, health-related quality of life and resource use.  Time 
to first complication was defined as the time from study registration until confirmed 
complication.  Patients who did not experience a complication were censored at the date of 
device removal, date of last chemotherapy if the device had not been removed, the date of 
withdrawal if the patient withdrew from the study prior to experiencing complications or date 
of death.  Health-related quality of life was assessed using a specifically designed 16-
question device-specific questionnaire (Appendix I) and the EuroQoL 5D (EQ-5D).  The EQ-
5D was recorded at baseline and monthly thereafter until device removal, death or end of 
follow-up.  Resource use was recorded as consultations with healthcare professionals 
(inpatient stay, outpatient visits and general practitioner consultations). Patients were 
recruited between August 2011 and July 2013; the 12-month follow up was completed in July 
2014.   
 
Statistical Analysis 
The sample size calculation was based on a randomised phase II screening approach to 
provide initial evidence of the effect of TIVAS in lowering the complication rate relative to 
Hickman catheters (Rubinstein et al., 2005) .  Only one UK study had previously compared 
Hickman and TIVAS-associated complications in patients undergoing chemotherapy (Ng et 
al., 2007), and reported a complication rate of approximately 60% with Hickman catheters.  
The current phase II trial was designed to have 82% power to produce a statistically 
significant result at the 20% one-sided level of statistical significance if the true complication 
rate with TIVAS is 40%.  This corresponds to an odds ratio (OR) of 2.25, which is at the low 
end of the estimates obtained from the wider literature (Carde et al., 1989, Dillon et al., 2004, 
Johansson et al., 2004, Kappers-Klunne et al., 1989, Mueller et al., 1992) .  The intention 
was to randomise 75 patients to Hickman catheters and 25 patients to TIVAS. 
 
All analyses were performed on the intention-to-treat principle.  Logistic regression was used 
for the primary analysis to compare the proportion of patients on each arm experiencing one 
or more complication; the model included the stratification variable used in the randomisation 
(BMI).  Time to first complication was analysed as a secondary endpoint using a Cox 
regression, also including BMI in the model.  Quality of life analysis was based on the device-
specific questionnaire.  Overall, 16 questions were graded on a scale of 1 (not at all) to 4 
(very much).  The worst score reported during the study was established for each question 
 6 
and these were compared across study arms via Mann-Whitney U tests.  The p-values for 
the individual questions were adjusted for multiple comparisons using the false-discovery 
rate approach (calculated using the p.adjust function of the stats library in R ([http://www.r-
project.org]). 
 
Pre-trial Economic Modelling 
A probabilistic decision analytical model was used to evaluate the potential cost-
effectiveness of Hickman catheters and TIVAS from the perspective of the UK NHS over the 
trial period (12 months).  A simple decision tree structure was adopted to identify patients 
who may and may not experience complications.  Data relating to complication rates, 
resource use, costs and health utilities were based on the results of the current phase II trial.  
The cost of Hickman catheters and TIVAS were costed at £80 and £300, respectively.  The 
costs associated with the devices were calculated by applying unit costs to healthcare 
resource use.  Health utilities and quality adjusted life years (QALYs) were calculated from 
the EQ-5D data.  Multiple imputation was used to impute missing values of the EQ-5D five 
dimensions (Rubin and Schenker, 1986) , and mean QALYs were estimated using the area 
under curve approach (Dolan, 1997) .  Where appropriate, cost-effectiveness was expressed 
as incremental cost per complication averted and incremental cost per QALY gained.  
Probabilistic (via a 1000 iteration Monte Carlo simulation) and univariate sensitivity analyses 
were undertaken to assess uncertainty.  
 
In order to examine if conducting a larger randomised controlled trial of Hickman lines versus 
TIVAS may be worthwhile, an expected value of perfect information (EVPI) analysis was 
carried out (Drummond et al., 2007) .  The analysis combined the probability and the cost of 
making the wrong decision, in terms of forgone health benefit and wasted resources based 
on uncertainty in the existing data.  For the model it was assumed that the life of technology 
is five years and the number of eligible patients per annum has been estimated at 425,000 
per annum in UK (HES data 2009-10).  A sample size calculation for a future trial was also 
undertaken based on the results of the economic evaluation using the net monetary benefit 
(NMB) approach (Appendix II) (Briggs, 2000) .  The estimates for both the cost and the 
effects were combined to determine the sample size for a cost-effectiveness outcome, using 
the traditional statistical methods for mean effectiveness, but based on the expected change 
in NMB (i.e. the change in monetarised effect minus the change in cost between the two 
alternatives) (Briggs, 2000, Armitage et al., 2002) .  
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RESULTS 
 
Seventy-four patients were randomised to Hickman catheters and 26 to TIVAS  (Figure 1).  
One patient randomised to the TIVAS arm received a Hickman catheter due to administrative 
error.  Three patients withdrew from the study prior to device insertion (2 Hickman arm and 1 
TIVAS arm).  Devices were all successfully placed in the 97 patients.  The majority (Hickman 
93% and TIVAS 84%) were inserted on the day of randomisation, and the remainder within 
six days.  No immediate complications occurred during device placement.  The two arms 
were well balanced for demographic and clinical baseline characteristics (Table 1).  
Colorectal, breast and pancreatic cancers made up the majority of the tumour types. 
 
Complications 
Forty (54%) Hickman patients reported one or more complication compared to 10 (38%) 
TIVAS patients (Table 2).  Based on the logistic regression model, taking into account BMI 
stratification, Hickman catheters were associated with a statistically significant increased risk 
(the threshold for statistical significance was based on the pre-defined statistical plan of this 
phase II study) of one or more complications compared with TIVAS devices (OR 2.07; 80%CI 
1.11, 3.88; exact one-sided p=0.068).   
 
There were 28 blood stream infections in total; 27 in 20 Hickman patients and in one TIVAS 
patient.  Blood stream infection was the commonest complication in the Hickman arm, 
accounting for 45% of the complications.  Fifteen patients, all in the Hickman arm required 
device removal due to blood stream infection.  There were 30 line occlusions; 19 in 15 
Hickman patients and 11 in six TIVAS patients.  Line occlusion was the commonest 
complication in the TIVAS arm accounting for 55% of the complications.  These were 
primarily resolved through simple catheter flushes and none required device removal in the 
TIVAS arm.  In contrast, two patients in the Hickman arm required device removal due to 
occlusion.  One patient in each arm had a confirmed central venous thrombosis; there were 
no reported pulmonary embolic events and no devices removed due to venous thrombosis.  
Overall, 21 devices were removed due to complications – 20 from the Hickman arm and one 
from the TIVAS arm.  In the Hickman arm these were for infection (15), line occlusion (2), 
device malfunction (1), wound/exit site infection (1) and other (1); in the TIVAS arm one 
single device was removed due to device malfunction.  The median time to first complication 
for the Hickman arm was 30 weeks (80%CI 19, not estimable).  The median time to first 
complication was not calculable for the TIVAS arm since less than 50% of the patients 
experienced a complication.   
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Chemotherapy was interrupted due to complications in 12 patients in the Hickman arm and 
two in the TIVAS arm.  In the Hickman arm the duration of chemotherapy interruption ranged 
from 4-41 days, and in the TIVAS arm both interruptions were for one day only.  
 
Quality of life 
Overall, quality of life based on the device-specific questionnaire was better in TIVAS 
patients than Hickman patients.  The adjusted one-sided p-values indicated that there were 
statistically significant differences at the 20% level in favour of TIVAS for all but three of the 
questions relating to “getting in and out of a car”, “using public transport” and “going out 
shopping” (Table 3). 
 
Cost-effectiveness 
In consequence to the higher complications rate, patients in the Hickman arm incurred 
significantly greater healthcare resource use than the TIVAS arm (Appendix III).  The health 
utilities fluctuated over the 12-month period in both arms.  In base-case analysis, Hickman 
catheters were associated with substantially greater mean cost (£2515 vs £712), fewer 
complications averted (62 vs 46, based on a cohort of 100 patients), and lower mean QALYs 
than TIVAS over a one-year period (Table 4).  However, the observed difference in QALYs 
between the devices is extremely small (0.64 vs 0.65).  Overall, the Hickman arm was 
associated with greater costs and lower health benefits, suggesting that TIVAS is the 
dominant strategy.   
 
Univariate sensitivity analysis was undertaken to examine the impact of complication rates by 
adopting data from the wider literature.  The probabilities of complications were estimated 
from pooling the results from the current phase II trial with two existing randomised controlled 
trials using on a random effects model (Carde et al., 1989, Kappers-Klunne et al., 1989).  The 
estimated pooled odds ratio for any complications was 3.05 (95%CI 1.08, 8.64); this was 
used in the analysis.  The difference in cost between Hickman catheters and TIVAS 
increased, but the impact on the QALYs was remained extremely small (Table 4).  The 
healthcare resource use among patients in the TIVAS arm was extremely low in the current 
phase II trial; this was also tested in the sensitivity analysis.  The mean cost of patient with 
complications was assumed to be the same in both arms; this has little impact on the overall 
results.  However, the model is most sensitive to the health utility estimates.  When the 
QALY estimates for the Hickman arm was increased by 20%, and when all health utilities 
estimates were adjusted for censoring, TIVAS was no longer the dominant strategy.  The 
results of the probabilistic sensitivity analysis following 1000 replications of the model are 
presented on the cost-effectiveness plane (Figure 2).  The majority of the point estimates 
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suggest that Hickman catheters were associated with greater costs than TIVAS, but there is 
substantial uncertainty in the difference in QALYs between the two devices.  The value of 
information analysis suggested that, given current decision uncertainty, and at a willingness 
to pay threshold of £20,000, additional research is potentially worthwhile if future research 
costs less than £42 million.   
 
Based on the base case, a sample of 507 per arm will be sufficient to show a positive NMB in 
favour of TIVAS, given the likely improvement in QALYs, rate of complications and potential 
cost savings compared to Hickman.  However, when taking into account the additional 
evidence from existing literature using the pooled odds ratio for any complications, the 
estimated NMA becomes greater in favour of TIVAS; the resultant required sample per arm 
was lower (323 per arm) 
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Discussion 
 
This pilot study found that Hickman catheters were associated with significantly greater risk 
of complications than ports (OR 2.07; 80%CI 1.11, 3.88).  These findings are in line with 
existing evidence (Kulkarni et al., 2014, Coady et al., 2015) . The most commonly reported 
complication in the Hickman arm was blood stream infection.  This is likely related to the 
external component of the device plus the need for more regular flushing (weekly).  In 
contrast with a totally implanted device, only one case of infection was observed.  In the 
TIVAS arm the most commonly reported complication was line occlusion (defined as inability 
to aspirate blood).  The decision analytical model showed that, despite the lower device 
costs, taking into account complications, Hickman catheters were associated with greater 
costs, fewer complications averted, but similar QALYs compared with TIVAS.  The TIVAS is 
the dominant strategy and is the cost-effective option.  However, the estimates were 
associated with substantial uncertainty, and the findings were highly sensitive to health utility 
estimates. 
 
The expected costs of uncertainty can be interpreted as the expected value of perfect 
information, based on the assumption that perfect information can eliminate the possibility of 
adopting the wrong decision.  This also represents the maximum that the healthcare system 
should be willing to pay for additional evidence to inform this decision in the future through 
further research.  At a cost-effectiveness threshold of £20,000 per QALY, based on the 
assumption that 425,000 patients may be eligible for venous catheters in the UK per year 
and a conservative expected lifetime of one year for the catheter, the EPVI for the effective 
population is approximately £42 million.  This represents the maximum that the healthcare 
system should be willing to pay for additional evidence to inform this decision in the future.   
 
This pilot trial was designed to generate information about potential recruitment rates, 
incidence of distribution of outcome events and the potential cost-effectiveness, to inform the 
design of a larger definitive randomised controlled trial by.  In terms of recruitment, the 
recruitment rate was poor at the initial 12 months.  However, this was resolved by introducing 
dedicated staff to act as ‘trial champion’.  The champion interacted with the patient pathway 
at all the important stages and successfully engaged with both healthcare staff and patients.   
In term of assessing complication rates, the definitions of complications were clear, but 
further refinements to the definitions of mechanical complications and line occlusions would 
ensure more accurate classification and coding.  For instance, line occlusion was the most 
frequently observed complications among patients with TIVAS.  Further investigations found 
that on several occasions when nursing staff was not able to aspirate blood return, this was 
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resolved by the medical staff successfully re-siting the needle into the TIVAS.  It is likely that 
several of these were misclassified as apparent ‘line occlusions’.  Training is important with 
both these devices in order to minimise complications.  At the start of this trial a TIVAS user-
training programme was instituted as these devices were not in regular use. Training and 
nurse confidence improved over the study period.  This could be a potential confounder in 
future trials.  
 
There were also limitations to the economic evaluation.  Healthcare resource use recorded in 
the TIVAS arm was surprisingly low, especially when compared to the Hickman arm.  This 
may reflect potential performance bias; the two senior radiologists who were responsible for 
insertion of the TIVAS were often involved in resolving TIVAS complications.  As a result, the 
costs associated with TIVAS may have been underestimated.  On the other hand, the 
EuroQol 5D was used to estimate health utilities associated with using the two devices, and 
showed very small differences between the two arms.  This may be explained by the results 
being dominated by the toxicity of the chemotherapy and disease status.  The device-specific 
quality of life questionnaire in contrast appeared sensitive to differences between the two 
devices with 13 of the 16 questions showing statistically significant differences.  The QALYs 
associated with TIVAS may have been underestimated.  Due to the small sample size, 
correlation between the two questionnaires was not explored.  The uncertainty associated 
with the QALY estimates was an important driver to the EVPI results.  There is a clear need 
for more accurate estimates of QALYs, which supports the conclusion that further research 
to reduce overall uncertainty is worthwhile. 
 
This study suggests that the most expensive and least used device (TIVAS) may in fact be 
the most cost-effective.  If confirmed with a larger trial, TIVAS could become the dominant 
strategy.  This will require a programme of both training and education across the UK where 
currently TIVAS are only used in a highly selective fashion and almost exclusively placed by 
medical staff.  
 
A much larger multicentre trial is needed which should also include PICC to establish clinical 
and cost-effectiveness.  The NIHR (HTA) has recently funded a large RCT comparing 
Hickman lines, TIVAS and PICC (HTA 11/67/01).  This trial (CAVA) of up to 2000 subjects, 
based on sample size calculation that took into account data from this Phase II study and the 
wider literature, is currently underway.  
 
 
CONCLUSIONS 
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Cancer is a leading cause of death and many patients are treated with chemotherapy. 
Intravenous chemotherapy often necessitates a long-term venous access device.  This pilot 
study provided preliminary evidence of a lower complication rate with TIVAS compared to 
Hickman catheters in patients receiving chemotherapy.  This difference resulted in the 
Hickman arm being associated with greater costs and lower health benefits than the TIVAS 
arm and hence being less cost-effective.  These preliminary findings need confirmation from 
a larger multi-centre phase III trial which should also include peripherally inserted central 
catheters which are currently the most common device used for chemotherapy delivery in the 
UK. 
 
The study was funded by a research grant from the Chief Scientist Office Scotland 
(CZG/2/512) and a small grant from Cook Medical UK.  The funders had no role in the design 
of the study, data collection, data analysis, data interpretation or the writing of the paper.  All 
authors assume responsibility for the accuracy and completeness of the data, and for the 
overall integrity of the article.  
 
 
 
  
Figure 1 Trial Profile 
 
 
 Table 1  
Demographic and clinical characteristics of the intention-to-treat population 
 
 
 Hickman (n=74) TIVAS (n=26) 
Demographic Characteristics   
Men 24 (32%) 12 (46%) 
Mean age, years 58 (SD 11)  57 (SD 12) 
White ethnic origin 74 (100%) 22 (85%) 
Clinical Characteristics   
BMI   
     <20 10 (14%) 4 (15%) 
     20 to <30 40 (54%) 13 (50%) 
     30 to <40 20 (27%) 7 (27%) 
     ≥40 4 (5%) 2 (8%) 
Cancer Type   
     Colorectal 23 (31%) 9 (35%) 
     Breast 25 (34%) 7 (27%) 
     Pancreas 4 (5%) 3 (12%) 
Metastatic disease 41 (55%) 15 (58%) 
TIVAS=totally implanted venous access system 
 
 
Table 2 Complications and Device Removal 
 
 Hickman Catheters TIVAS 
 No. of Patients No. of Complications No. of Patients No. of Complications 
Any Complications     
     No complications 34 (46%)  16 (62%)  
     1 complication 25 (34%)  4 (15%)  
     2 complications 12 (16%)  3 (12%)  
     3 complications 1 (1%)  2 (8%)  
     4 complications 2 (3%)  1 (4%)  
Total number of patients 74 (100%)  26 (100%)  
Complication Type     
     Blood stream infection 20 (27%) 27 (45%) 1 (4%) 1 (5%) 
     Wound and exit site infection 4 (5%) 4 (7%) - -  
     Line occlusion 15 (20%) 19 (32%) 6 (23%) 11 (55%) 
     Device malfunction 2 (3%) 2 (3%) 3 (12%) 3 (15%) 
     Venous thrombosis 1 (1%) 1 (2%) 1 (4%) 2 (10%) 
     Other* 6 (8%) 7 (12%) 3 (12%) 3 (15%) 
Total number of complications  60 (100%)  20 (100%) 
Complication led to Device Removal     
     Blood stream infection  15/27  0/1 
     Wound and exit site infection  1/4  - 
     Line occlusion  2/19  0/11 
     Device malfunction  1/2  1/3 
     Venous thrombosis  0/1  0/2 
     Other*  1/7  0/3 
Device Removal (N = 72)  (N = 24)  
     Planned removal 33 (46%)  3 (13%)  
     Removal due to complications 20 (28%)  1 (4%)  
     Removal due to patient preference 2 (3%)  -  
     Removal due to other reasons§ 17 (24%)  20 (83%)  
TIVAS=totally implanted venous access system  *Other complications include suspected infection (3), minor bleeding at exit site (1) and a broken suture (1) in the Hickman group and discomfort at 
insertion site (1), training issue (1) and transfer to another hospital (1) in the TIVAS group. §Removal due to other reasons: device in situ ≥12 months (2 Hickman, 5 TIVAS), end of treatment (3 
Hickman), patient died (9 Hickman, 13 TIVAS), other (3 Hickman, 2 TIVAS 
 
Table 3  
Probabilistic Results of the Cost-Effectiveness Analysis 
 
  
Mean Costs 
No. of Complications  
Averted* 
 
Mean QALYS 
Base case Analysis    
Hickman Lines £2515 46 0.64 
TIVAS £712 62 0.65 
Difference (Hickman minus TIVAS) £1803 (95%CI 462, 3215) -16 (95%CI -36, 5) -0.01 (95%CI -0.15, 0.15) 
 
Sensitivity Analysis – risk of complications estimated from meta-analysis 
 
Hickman Lines £2507 46 0.63 
TIVAS £708 60 0.64 
Difference (Hickman minus TIVAS) £1800 (95%CI 585, 3185) -16 (95%CI -38, 8) -0.01 (95%C -0.15, 0.14) 
 
Sensitivity Analysis – mean cost of patient with complications in TIVAS = Hickman  
 
Hickman Lines £2522 46 0.63 
TIVAS £1965 62 0.65 
Difference (Hickman minus TIVAS) £557 (95%CI -1058, 2233) -16 (95%CI -36, 5) -0.01 (95%CI -0.15, 0.14) 
 
Sensitivity Analysis – health utilities in Hickman arm +20% 
 
Hickman Lines £2509  0.76 
TIVAS £720  0.65 
Difference (Hickman minus TIVAS) £1789 (95%CI 417, 3296)  0.11 (95%CI -0.03, 0.25) 
 
Sensitivity Analysis – health utilities in TIVAS arm +20% 
 
Hickman Lines £2522  0.63 
TIVAS £715  0.78 
Difference (Hickman minus TIVAS) £1807 (95%CI 469, 3248)  -0.14 (95%CI -0.28, 0.01) 
 
Sensitivity Analysis – health utilities adjusted for censoring (Kaplan-Meier Sample Estimator) (Gray et al.) 
 
Hickman Lines £2537  0.62 
TIVAS £716  0.55 
Difference (Hickman minus TIVAS) £1821 (95%CI 510, 3251)  0.07 (95%CI -0.07, 0.21) 
TIVAS=totally implanted venous access system  *Number of complications averted was based on a cohort of 100 patients 
 
Table 4 Quality of Life Impact based on Device-specific Questionnaire 
 
 
 Unadjusted Adjusted 
Driving a car 0.046 0.074 
Getting in or out of a car 0.265 0.303 
Using public transport 0.483 0.483 
Going out shopping 0.426 0.454 
Eating 0.111 0.148 
Hygiene <0.001 <0.001 
Sleeping 0.057 0.083 
Mobility or movement 0.154 0.190 
Normal work activity 0.009 0.021 
Exercise <0.001 <0.001 
Hobbies 0.023 0.041 
Self-consciousness 0.002 0.005 
Socialising 0.022 0.041 
At risk of infection <0.001 <0.001 
At risk of damaging device <0.001 <0.001 
Negative impact on quality of life 0.001 0.003 
 
 
Figure 2 
Probabilistic analysis based on 1000 simulations (Hickman versus TIVAS) 
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Appendix I 
 
Venous access device and EQ-5D Quality of life questionnaire 
 
 
Does the access device reduce your ability to carry out the following day to day 
activities? 
 
 Not at all A little Quite a bit Very much 
 1 2 3 4 
Driving a car     
Getting out of a car     
Using public transport     
Going out shopping     
 
Does the access device affect you ability to carry out normal day to day activities such 
as:  
 
 Not at all A little Quite a bit Very much 
Eating 1 2 3 4 
Hygiene – washing, bathing, showering, 
hair brushing, drying yourself, etc. 
    
Sleeping     
Mobility or movement     
Normal work activity     
Exercise – swimming, et.     
Hobbies – gardening, etc.     
Does the access device make you self 
conscious? 
    
Has it affected your socialising?     
Do you feel at risk of infecting the access 
device? 
    
Do you feel at risk of damaging the access 
device? 
    
To what extent has the presence of the 
access device had a negative impact on 
your quality of life ? 
    
 
  
Appendix II 
 
Sample Size Calculations 
 
Design considerations are different for clinical and economic analyses and therefore it is 
important to ensure that when economic evaluations are conducted alongside clinical trials 
they are adequately powered for the cost-effectiveness analysis (Briggs et al, 2000). 
Consideration must be given to whether the sample size calculated for the clinical trial based 
on the effectiveness outcome alone is also sufficiently powered for the joint cost-
effectiveness result. 
 
A sample size calculation for the future trial was undertaken using the net monetary benefit 
(NMB) approach, based on the outcomes from this feasibility trial and following the sample 
size formula and methodology as detailed by Glick et al. (Glick and Doshi, 2011; Glick H, 
2010).  The endpoints of interest from the feasibility trial are the difference in probability of 
complications between arms (no complications is an improvement in effectiveness), the 
difference in quality adjusted life years (QALYs), and the difference in costs, as detailed in 
Table 1.  
 
 
Table 1 Outcomes from the feasibility trial 
Outcome No complications QALYs Cost 
Hickman 0.54 0.64 2525 
TIVAS 0.38 0.65 712 
Difference -0.16 0.01 -£1809 
 
 
The predictions from this feasibility study have shown potential cost-savings, with a reduction 
in complications using TIVAS, but there was no significant difference on the QALY outcomes.  
 
The sample size calculations have been calculated using the expected difference in costs 
(ΔC) between arms and the expected difference in QALYs, which is the preferred economic 
outcome of effectiveness (NICE, 2013). As the primary outcome for the definitive trial will be 
probability of complications, sample size was also recalculated using the difference in 
probability of complications (ΔE) to ensure sufficient power for both a within trial and lifetime 
cost-effectiveness analysis.  A monetary ‘willingness to pay’ value (λ) is estimated to reflect 
the monetary value of a QALY or of avoiding complications, based on the recommended UK 
threshold (NICE 2013).  Table 2 details the parameters for the sample size calculations.  The 
feasibility study showed there is a negative correlation between costs and outcomes: an 
increase in effectiveness (reduction in complications or improvement in QALYs) gives rise to 
a reduction in costs.  When undertaking NMB sample size calculations the direction of the 
correlation between costs and effects can have a substantial impact on the sample size 
requirement (Glick, 2011).  
 
 
  
Table 2 Parameters for NMB Sample Size Calculations 
Parameter Value Descritpiton 
C∆ -£1808 Difference in costs 
VarC £1523 Variance costs 
QALY∆ 0.01 Difference in effect (QALYs) 
VarQALY 0.4604 Variance QALYs 
E∆ 0.16 Difference in effect (probability no complications) 
VarE 0.485 Variance effect 
λ £20,000 Willingness to pay value (NICE ceiling ratio) 
Power 0.9 Beta 
Significance 0.05 Alpha 
ρ -0.5 correlation of the difference in costs and effects 
 
 
Table 3 details the required sample size for the Hickman versus TIVAS comparison to detect 
a positive NMB in favour of Port at a power of 90%, 80%, 70%.  The first column calculates 
the NMB sample size using costs and QALYs, while the second column calculates the NMB 
sample size using costs and reduction in complications.  For the economic analysis the 
preferred outcome is incremental cost per QALY as this reflects the long-term impacts 
(NICE, 2013). 
 
Table 3 Sample size per arm  
 
Estimation based on 
costs and QALYs 
Estimation based on costs and 
complications averted 
Power 
  90% 507 97 
80% 379 72 
70% 298 57 
 
The sample size requirements when using QALYs as the effect point of interest are much 
greater than when using the probability of avoiding complications.  This is driven by the size 
of the difference between arms in these effect measures, as detailed in Table 1.  The 
difference in probability of complications between Hickman and TIVAS is 0.54 versus 0.38 
(0.16), which is much greater than the difference in QALYs 0.64 vs 0.65 (0.01), and 
therefore, as the QALY calculation has more uncertainty in the difference in effect, a much 
greater sample size is required to show a significant NMB which is greater than zero.    
 
The predictions from the feasibility study have shown potential cost-savings, with a reduction 
in complications using TIVAS, but no significant difference on the QALY outcomes.  
Therefore, the NMB sample size calculations for QALY outcomes are much larger than the 
sample size required based on the effectiveness outcome (reduction in complications). 
 
Sensitivity analysis using pooled risk of complications from the literature (OR 3.05; 95% 1.08, 
8.64) projected greater NMB when comparing Hickman with TIVAS.  Consequently, the 
sample size requirements were estimated to be lower overall – for 90% power, estimation 
based on costs and QALYs required 323 individuals per arm; estimation based on costs and 
complications averted required 84 individuals per arm. 
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